Your browser is no longer supported. Please, upgrade your browser.
PTCT PTC Therapeutics, Inc. daily Stock Chart
PTCT [NASD]
PTC Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.35 Insider Own0.50% Shs Outstand66.17M Perf Week5.50%
Market Cap2.82B Forward P/E- EPS next Y-2.15 Insider Trans-36.78% Shs Float60.65M Perf Month-23.22%
Income-251.60M PEG- EPS next Q-1.31 Inst Own85.61% Short Float8.16% Perf Quarter-11.90%
Sales307.00M P/S9.17 EPS this Y-55.40% Inst Trans0.22% Short Ratio4.97 Perf Half Y25.25%
Book/sh9.58 P/B4.44 EPS next Y54.40% ROA-17.20% Target Price50.43 Perf Year13.52%
Cash/sh10.37 P/C4.10 EPS next 5Y-9.51% ROE-44.50% 52W Range30.79 - 59.89 Perf YTD-11.39%
Dividend- P/FCF- EPS past 5Y-7.50% ROI-27.80% 52W High-28.94% Beta1.56
Dividend %- Quick Ratio3.20 Sales past 5Y64.80% Gross Margin96.00% 52W Low38.22% ATR4.19
Employees754 Current Ratio3.30 Sales Q/Q11.80% Oper. Margin-78.60% RSI (14)45.27 Volatility8.36% 10.86%
OptionableYes Debt/Eq0.53 EPS Q/Q-30.50% Profit Margin-82.00% Rel Volume0.62 Prev Close44.96
ShortableYes LT Debt/Eq0.49 EarningsMar 02 AMC Payout- Avg Volume996.34K Price42.56
Recom1.90 SMA20-1.02% SMA50-14.71% SMA200-6.05% Volume612,824 Change-5.34%
Feb-20-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-20-20Downgrade Citigroup Buy → Neutral $55 → $71
Nov-12-19Initiated SunTrust Buy $78
May-13-19Upgrade BofA/Merrill Neutral → Buy $43 → $49
Apr-11-19Initiated Bernstein Outperform $48
Oct-03-18Upgrade BofA/Merrill Underperform → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $66
Jul-19-18Initiated Credit Suisse Outperform $49
Jun-18-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-04-18Downgrade Barclays Equal Weight → Underweight $24 → $26
Jan-29-18Resumed RBC Capital Mkts Sector Perform
Nov-16-17Upgrade JP Morgan Underweight → Neutral
Oct-26-17Downgrade BofA/Merrill Neutral → Underperform
Oct-09-17Downgrade JP Morgan Neutral → Underweight
Sep-29-17Reiterated RBC Capital Mkts Sector Perform
Sep-29-17Reiterated Barclays Equal Weight $22 → $15
Aug-23-17Initiated William Blair Mkt Perform
Mar-16-17Reiterated RBC Capital Mkts Sector Perform $13 → $10
Mar-03-17Downgrade Barclays Overweight → Equal Weight $20 → $13
Nov-14-16Upgrade Credit Suisse Neutral → Outperform
Mar-30-20 06:06PM  FDA Decisions on 5 Drugs Expected in 2nd Quarter GuruFocus.com +5.45%
Mar-29-20 12:32PM  Do Hedge Funds Love PTC Therapeutics, Inc. (PTCT)? Insider Monkey
Mar-25-20 09:04AM  Edited Transcript of PTCT earnings conference call or presentation 2-Mar-20 9:30pm GMT Thomson Reuters StreetEvents
Mar-16-20 08:00AM  PTC Therapeutics Announces Management Change PR Newswire -26.33%
Mar-11-20 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire -8.32%
Mar-10-20 11:53AM  The Surprising Impact Coronavirus Will Have On Biotech Companies Investor's Business Daily
Mar-04-20 09:40AM  Earnings Update: PTC Therapeutics, Inc. Just Reported And Analysts Are Trimming Their Forecasts Simply Wall St. +9.33%
Mar-02-20 05:25PM  PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:01PM  PTC Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides a Corporate Update PR Newswire
Feb-25-20 04:30PM  PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
Feb-24-20 12:30PM  Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-18-20 08:00AM  PTC Therapeutics Launches Sixth Annual STRIVE Awards Program for Advocacy Organizations in Duchenne Muscular Dystrophy PR Newswire
Feb-17-20 04:30PM  PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results PR Newswire
Feb-06-20 04:08PM  This Biotech Stock Fell, Then Rose, And Prodded Biogen Into A Two-Day Run Investor's Business Daily
10:41AM  Is PTC Therapeutics, Inc. (NASDAQ:PTCT) A Volatile Stock? Simply Wall St.
05:00AM  SUNFISH Pivotal Results for Risdiplam (RG7916) Demonstrate Medically Meaningful Benefit in Broadest Age Group of Patients Studied with Type 2 and 3 Spinal Muscular Atrophy PR Newswire
Feb-03-20 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08:05AM  PTC Therapeutics to Host A Conference Call to Review Part 2 of the SUNFISH Clinical Trial Data at the SMA Europe Conference PR Newswire
08:00AM  PTC Therapeutics Announces First Publication of Real-World Data Showing Translarnaä (ataluren) Significantly Preserves Ability to Walk for Longer in Children with Duchenne Muscular Dystrophy PR Newswire
Jan-23-20 08:51AM  Roche's Risdiplam Meets Primary Endpoint in Infants Study Zacks
01:00AM  Risdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants with Type 1 Spinal Muscular Atrophy PR Newswire
Jan-13-20 08:00AM  PTC Therapeutics Provides Corporate Update and Highlights Pipeline Progress at 2020 J.P. Morgan Healthcare Conference PR Newswire
Jan-07-20 12:09PM  Why PTC Therapeutics, Inc.'s (NASDAQ:PTCT) CEO Pay Matters To You Simply Wall St.
Jan-06-20 08:00AM  PTC Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-26-19 11:58AM  Hedge Fund Favorites vs. PTC Therapeutics, Inc. (PTCT) In 2019 Insider Monkey
Dec-19-19 10:09AM  4 Drug/Biotech Outperformers That May Lose Steam in 2020 Zacks
Dec-13-19 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Dec-04-19 10:23PM  Hedge Funds Have Never Been This Bullish On PTC Therapeutics, Inc. (PTCT) Insider Monkey
Dec-03-19 10:09AM  The Therapeutics (NASDAQ:PTCT) Share Price Is Up 289% And Shareholders Are Boasting About It Simply Wall St.
Nov-29-19 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Nov-25-19 04:59PM  Roche's NDA for SMA Drug Risdiplam Gets Priority Review Zacks
Nov-21-19 11:22AM  Credit Suisse: 3 Strong Buy Stocks That Are Poised to Beat the Market TipRanks
Nov-19-19 08:00AM  PTC Therapeutics to Present at the Evercore ISI 2nd Annual HealthCONx Conference PR Newswire
Nov-18-19 08:00AM  PTC Therapeutics Launches A No-Cost Testing Program to Drive AADC Deficiency Patient Identification PR Newswire
Nov-12-19 09:43AM  Roche's SMA Drug Meets Primary Endpoint in Pivotal Study Zacks
Nov-11-19 01:00AM  Risdiplam (RG7916) Pivotal SUNFISH Study Demonstrates Statistically Significant Improvement for Patients with Type 2/3 Spinal Muscular Atrophy PR Newswire
Nov-04-19 11:42PM  Edited Transcript of PTCT earnings conference call or presentation 29-Oct-19 8:30pm GMT Thomson Reuters StreetEvents
Oct-31-19 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Oct-29-19 06:55PM  PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM  PTC Therapeutics Reports Third Quarter 2019 Financial Results and Provides a Corporate Update PR Newswire
Oct-24-19 12:26PM  When Will PTC Therapeutics, Inc. (NASDAQ:PTCT) Become Profitable? Simply Wall St.
08:00AM  PTC Therapeutics Announces Results from Long-Term AADC Deficiency Gene Therapy Treatment Demonstrating Sustained Improvements PR Newswire
Oct-23-19 06:45PM  Is PTC Therapeutics, Inc. (PTCT) A Good Stock To Buy ? Insider Monkey
04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Oct-15-19 08:31AM  PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2019 Financial Results PR Newswire
Oct-07-19 08:00AM  PTC Therapeutics Establishes Strategic Collaboration with Aldevron to Support GMP Plasmid Manufacturing PR Newswire
Oct-04-19 08:00AM  PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy PR Newswire
Oct-02-19 08:00AM  Risdiplam Spinal Muscular Atrophy Data Demonstrating Continued Benefit Presented at World Muscle Society Congress PR Newswire +5.65%
Sep-27-19 08:00AM  PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
Sep-20-19 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Sep-18-19 11:34AM  Is Therapeutics (NASDAQ:PTCT) Using Debt Sensibly? Simply Wall St. -11.29%
08:25AM  PTC Therapeutics Announces Pricing of Private Offering of Convertible Senior Notes PR Newswire
08:24AM  PTC Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire
Sep-17-19 04:01PM  PTC Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
04:01PM  PTC Therapeutics Announces Proposed Private Offering of Convertible Senior Notes PR Newswire
Sep-11-19 03:03PM  Edited Transcript of PTCT earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Sep-06-19 08:00AM  PTC Therapeutics Celebrates the Fifth Anniversary of STRIVE Grant Awards by Announcing 2019 Award Winners PR Newswire
Aug-19-19 10:51AM  Does PTC Therapeutics, Inc. (NASDAQ:PTCT) Have A Volatile Share Price? Simply Wall St.
Aug-07-19 02:24AM  PTC Therapeutics (PTCT) Q2 2019 Earnings Call Transcript Motley Fool
Aug-06-19 06:25PM  PTC Therapeutics (PTCT) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM  PTC Therapeutics Reports Second Quarter 2019 Financial Results and Provides a Corporate Update PR Newswire
Aug-05-19 08:00AM  PTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility PR Newswire
Jul-31-19 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jul-30-19 10:38AM  PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks
Jul-23-19 08:00AM  PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2019 Financial Results PR Newswire
Jul-19-19 08:09AM  Should You Worry About PTC Therapeutics, Inc.'s (NASDAQ:PTCT) CEO Pay Cheque? Simply Wall St.
Jul-10-19 05:41PM  5 Health Care Stocks in Gurus' Portfolios GuruFocus.com
Jul-01-19 09:21AM  Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study Zacks
08:00AM  PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics PR Newswire
Jun-28-19 06:40AM  PTC Provides Update on Translarna (ataluren) Application for Label Expansion PR Newswire
Jun-14-19 01:49PM  Did You Miss Therapeutics's (NASDAQ:PTCT) Whopping 511% Share Price Gain? Simply Wall St.
Jun-13-19 09:44AM  Hedge Funds Have Never Been This Bullish On PTC Therapeutics, Inc. (PTCT) Insider Monkey
Jun-07-19 03:02PM  PTC Therapeutics Shares Spike After FDA Approves Drug For Younger Patients Benzinga
01:31PM  PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age PR Newswire
Jun-03-19 08:00AM  PTC Therapeutics Promotes Emily Hill to Chief Financial Officer PR Newswire
May-31-19 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
May-30-19 08:00AM  PTC Therapeutics to Participate at Upcoming Investor Conference PR Newswire
May-20-19 08:00AM  PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders PR Newswire
May-09-19 04:05PM  PTC Therapeutics and MRI Interventions Announce Strategic Investment PR Newswire
May-08-19 04:12PM  Edited Transcript of PTCT earnings conference call or presentation 2-May-19 8:30pm GMT Thomson Reuters StreetEvents +7.89%
08:00AM  PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
May-07-19 04:33PM  This Biotech Has A 'Swing Factor' In SMA Drugs And It's Slugging Biogen Investor's Business Daily
01:00AM  Data from Pivotal FIREFISH and SUNFISH Studies Demonstrate Clinical Benefit of Risdiplam in Type 1, 2, & 3 Spinal Muscular Atrophy Patients PR Newswire
May-03-19 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
May-02-19 07:15PM  PTC Therapeutics (PTCT) Reports Q1 Loss, Lags Revenue Estimates Zacks
06:07PM  PTC Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  PTC Therapeutics Reports First Quarter 2019 Financial Results and Provides a Corporate Update PR Newswire
May-01-19 12:48PM  Here is What Hedge Funds Think About PTC Therapeutics, Inc. (PTCT) Insider Monkey
Apr-29-19 09:18AM  Translarna (ataluren) is the First Therapy Approved in Brazil for Duchenne Muscular Dystrophy PR Newswire
Apr-25-19 10:33AM  Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-18-19 08:00AM  PTC Therapeutics to Host Conference Call to Discuss First Quarter 2019 Financial Results PR Newswire
Apr-12-19 08:28AM  Have Insiders Been Selling PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares? Simply Wall St.
Apr-01-19 08:00AM  Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders CNW Group
Mar-16-19 08:06AM  Edited Transcript of PTCT earnings conference call or presentation 28-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-15-19 03:43PM  Is PTC Therapeutics, Inc.s (NASDAQ:PTCT) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Mar-06-19 07:55AM  Research Report Identifies E*TRADE Financial, Kennedy-Wilson, Alteryx, PTC Therapeutics, Ocean Power Technologies, and NuVasive with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-04-19 04:30PM  PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
08:00AM  PTC to Expand Product Portfolio in Latin America with WAYLIVRA PR Newswire
Mar-01-19 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
02:29AM  PTC Therapeutics Inc (PTCT) Q4 2018 Earnings Conference Call Transcript Motley Fool
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHMERTZLER MICHAELDirectorMar 16Buy32.4810,000324,846100,066Mar 18 05:05 PM
Souza MarcioChief Operating OfficerFeb 10Option Exercise12.926258,0757,369Feb 12 04:09 PM
Souza MarcioChief Operating OfficerFeb 10Sale53.9262533,7006,744Feb 12 04:09 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 06Option Exercise10.8550,000542,50073,987Feb 07 04:41 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 06Sale55.004,040222,2001,912Feb 07 04:41 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 06Sale55.0050,0002,750,00027,089Feb 07 04:41 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 05Sale55.0040522,2755,952Feb 07 04:41 PM
Hill Emily LuisaChief Financial OfficerJan 23Sale53.2533017,5726,891Jan 27 04:14 PM
Peltz Stuart WalterChief Executive OfficerJan 23Sale53.2542322,52318,102Jan 27 04:12 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 23Sale53.25462,4495,987Jan 27 04:09 PM
Souza MarcioChief Operating OfficerJan 23Sale53.251548,2005,074Jan 27 04:15 PM
Utter Christine MarieSVP, Finance & CAOJan 07Option Exercise15.7813,750216,95012,724Jan 08 06:07 PM
Hill Emily LuisaChief Financial OfficerJan 07Sale49.62633,1267,221Jan 08 06:03 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 07Sale49.62592,9286,033Jan 08 06:06 PM
Utter Christine MarieSVP, Finance & CAOJan 07Sale50.0213,750687,7335,224Jan 08 06:07 PM
Souza MarcioChief Operating OfficerJan 06Sale48.17864,1425,228Jan 08 06:09 PM
Utter Christine MarieSVP, Finance & CAOJan 06Sale48.1736017,3405,224Jan 08 06:07 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 06Sale48.171276,1176,092Jan 08 06:06 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 06Sale48.1750724,42116,889Jan 08 06:06 PM
Peltz Stuart WalterChief Executive OfficerJan 06Sale48.1779838,43818,525Jan 08 06:04 PM
Peltz Stuart WalterChief Executive OfficerJan 06Sale48.171,79786,55823,085Jan 08 06:04 PM
Hill Emily LuisaChief Financial OfficerJan 06Sale48.1732115,4627,284Jan 08 06:03 PM
Utter Christine MarieSVP, Finance & CAOJan 03Option Exercise11.237888,8496,372Jan 06 04:52 PM
Utter Christine MarieSVP, Finance & CAOJan 03Sale47.4278837,3675,584Jan 06 04:52 PM
Utter Christine MarieSVP, Finance & CAOJan 02Option Exercise11.232,36226,5257,946Jan 06 04:52 PM
Utter Christine MarieSVP, Finance & CAOJan 02Sale47.892,362113,1115,584Jan 06 04:52 PM
Souza MarcioChief Operating OfficerDec 23Option Exercise12.926,25080,75011,288Dec 26 05:24 PM
Souza MarcioChief Operating OfficerDec 23Option Exercise14.4275,8811,094,54468,221Dec 26 05:24 PM
Souza MarcioChief Operating OfficerDec 23Sale48.806,250305,0005,038Dec 26 05:24 PM
Souza MarcioChief Operating OfficerDec 23Sale48.9096,6954,728,73238,221Dec 26 05:24 PM
Peltz Stuart WalterChief Executive OfficerDec 03Option Exercise13.9718,981265,16926,332Dec 05 04:50 PM
Peltz Stuart WalterChief Executive OfficerDec 03Sale50.0022,4631,123,15018,676Dec 05 04:50 PM
Boulding Mark ElliottExec. VP and CLOJul 05Option Exercise15.1015,312231,27933,899Jul 09 04:54 PM
Boulding Mark ElliottExec. VP and CLOJul 05Sale44.7415,312685,09729,524Jul 09 04:54 PM
Boulding Mark ElliottExec. VP and CLOJul 01Option Exercise24.23104,0922,521,639100,373Jul 02 06:46 PM
Utter Christine MarieSVP, Finance & CAOJul 01Option Exercise20.8113,071271,96814,234Jul 02 09:40 PM
Boulding Mark ElliottExec. VP and CLOJul 01Sale45.00104,0924,684,14029,524Jul 02 06:46 PM
Utter Christine MarieSVP, Finance & CAOJul 01Sale45.1513,071590,1434,937Jul 02 09:40 PM
Utter Christine MarieSVP, Finance & CAOJun 28Option Exercise20.8198820,5575,640Jul 02 09:40 PM
Boulding Mark ElliottExec. VP and CLOJun 28Option Exercise11.3577,575880,72373,614Jul 02 06:46 PM
Boulding Mark ElliottExec. VP and CLOJun 28Sale45.0077,5753,490,87529,524Jul 02 06:46 PM
Utter Christine MarieSVP, Finance & CAOJun 28Sale45.0098844,4604,937Jul 02 09:40 PM
Souza MarcioChief Operating OfficerJun 03Sale40.385,490221,68658,664Jun 04 09:09 PM